Urantide Conformation and Interaction with the Urotensin-II Receptor

被引:13
|
作者
Brancaccio, Diego [1 ]
Limatola, Antonio [1 ]
Campiglia, Pietro [2 ]
Gomez-Monterrey, Isabel [1 ]
Novellino, Ettore [1 ]
Grieco, Paolo [1 ]
Carotenuto, Alfonso [1 ]
机构
[1] Univ Naples Federico II, Dipartimento Farm, I-80131 Naples, Italy
[2] Univ Salerno, Dept Pharm, I-84100 Salerno, Italy
关键词
Atherosclerosis; Conformation by NMR; Docking studies; Therapeutic peptide; Urotensin-II; BINDING MODE; CRYSTAL-STRUCTURE; DICARBA-ANALOGS; ORPHAN RECEPTOR; MESSENGER-RNA; PEPTIDE; INSIGHT; IDENTIFICATION; LIGANDS; PROGRAM;
D O I
10.1002/ardp.201300269
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Urotensin II (U-II) is a disulfide bridged peptide hormone identified as the ligand of a G protein-coupled receptor. Human U-II (H-Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) has been described as the most potent vasoconstrictor compound identified to date. We have previously identified the compound termed urantide (H-Asp-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH), which is the most potent UT receptor (UTR) antagonist described to date. Urantide may have potential clinical value in the treatment of atherosclerosis. In the present study, we studied the conformational preferences of urantide in DPC micelles and developed a urantide/UTR interaction model. This model can help the design of novel peptides and small molecules as UTR antagonists.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 50 条
  • [21] Non-peptidic urotensin-II receptor modulators
    Jin, J
    Douglas, SA
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2006, 16 (04) : 467 - 479
  • [22] The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats
    Zhao, Juan
    Yu, Quan-Xin
    Kong, Wei
    Gao, Hai-Cheng
    Sun, Bo
    Xie, Ya-Qin
    Ren, Li-Qun
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 5 (06) : 1765 - 1769
  • [23] Isochromanone-based urotensin-II receptor agonists
    Lehmann, F
    Currier, EA
    Olsson, R
    Hacksell, U
    Luthman, K
    BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (08) : 3057 - 3068
  • [24] Ligand-Supported Purification of the Urotensin-II Receptor
    Du, Ann T.
    Onan, Doene
    Dinh, Diem T.
    Lew, Michael J.
    Ziogas, James
    Aguilar, Marie-Isabel
    Pattenden, Leonard K.
    Thomas, Walter G.
    MOLECULAR PHARMACOLOGY, 2010, 78 (04) : 639 - 647
  • [25] New insight into the binding mode of peptides at urotensin-II receptor by Trp-constrained analogues of P5U and urantide
    Carotenuto, Alfonso
    Auriemma, Luigia
    Merlino, Francesco
    Limatola, Antonio
    Campiglia, Pietro
    Gomez-Monterrey, Isabel
    Bianca, Roberta d'Emmanuele di Villa
    Brancaccio, Diego
    Santicioli, Paolo
    Meini, Stefania
    Maggi, Carlo Alberto
    Novellino, Ettore
    Grieco, Paolo
    JOURNAL OF PEPTIDE SCIENCE, 2013, 19 (05) : 293 - 300
  • [26] Discovery of new potent antagonist at urotensin-II receptor
    Sala, M.
    Auriemma, L.
    Campiglia, P.
    Monterrey-Gomez, I.
    Santicioli, P.
    Maggi, C. A.
    Rovero, P.
    Carotenuto, A.
    Novellino, E.
    Grieco, P.
    BIOPOLYMERS, 2007, 88 (04) : 604 - 604
  • [27] Urotensin-II gene polymorphism and serum urotensin-II levels in children with Bartter syndrome
    Balat, Ayse
    Koc, Gulsah
    Soyocak, Ahu
    Kilic, Beltinge Demircioglu
    Kara, Mehtap
    Buyukcelik, Mithat
    Noyan, Z. Aytul
    Bilge, Ilmay
    Ates, Funda Seher Ozalp
    PEDIATRIC NEPHROLOGY, 2024, 39 (01) : S346 - S346
  • [28] Behavioral actions of urotensin-II
    do Rego, Jean-Claude
    Leprince, Jerome
    Scalbert, Elizabeth
    Vaudry, Hubert
    Costentin, Jean
    PEPTIDES, 2008, 29 (05) : 838 - 844
  • [29] Is urotensin-II the new endothelin?
    Maguire, JJ
    Davenport, AP
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (05) : 579 - 588
  • [30] Urotensin-II and cardiovascular remodeling
    Papadopoulos, Panayiota
    Bousette, Nicolas
    Giaid, Adel
    PEPTIDES, 2008, 29 (05) : 764 - 769